Longevity Magazine A review journal of healthspan, preventative medicine and ageing
Review journal · Independent · United Kingdom

Claims about ageing, graded against the evidence for them

Eight reviews. Each grades one stated claim from A to D, gives the reasoning, and says what would change it.

8 graded reviews4 explainers4 analysis piecesLast checked 31 July 2026

What this is

Longevity Magazine is a review journal covering healthspan, preventative medicine and the biology of ageing. Each review grades one stated claim from A to D against a published methodology, describes the evidence qualitatively rather than quoting figures, and says in advance what would change the grade. It is independent, sells nothing, and gives no medical advice.

What this journal does

Claims about ageing are made in a market where the outcomes of interest take decades to measure and the products are on sale now. The result is a familiar kind of writing: a real mechanism, a real laboratory finding, and a silent step to a conclusion about human health that nobody has tested.

Every review here grades a single stated claim, states the grade at the top with the reasoning that produced it, and sets out what evidence would move it. Grades run from A to D and attach to claims rather than to substances, so the same compound can carry different grades for different assertions about it.

Evidence is described qualitatively throughout. A review will tell you that a field's trials are small, short, conducted in healthy volunteers, funded by manufacturers and not independently replicated. It will not name a study or quote a figure, for reasons set out in the editorial policy.

The four evidence grade bands, A at the top to D at the bottomAReplicated, adequately powered, clinical outcomesBOne adequately powered trial, or consistent large cohortsCShort, small or surrogate-outcome human data onlyDPreclinical, or human data too sparse to support the claim
FigureThe grading ladder used throughout the journal. A grade attaches to a stated claim, never to a substance in general.

Where the field currently stands

Of the eight claims graded in this journal, none holds grade A on an interventional basis. One prognostic claim does. The rest sit at C or D, which means either that the human evidence is short and surrogate-based, or that the work remains preclinical.

That distribution is the most useful single fact we can offer. It is not a statement that the science is poor. Several of these fields contain excellent work. It is a statement that the claims being made in public have largely not been tested in the populations and over the durations the claims concern, and that the gap between the two is where a reader's money and risk sit.

The two claims with the strongest support concern physical activity, an intervention with no commercial sponsor and no product attached. That is worth noticing.

Claim reviewedGradeClaim type
NAD precursors, NMN and NRDIntervention claimRead the review
Metformin for healthspanCIntervention claimRead the review
Rapamycin and mTORDIntervention claimRead the review
SenolyticsDIntervention claimRead the review
VO2 max as a markerAPrognostic claimRead the review
Resistance trainingBPrognostic claimRead the review
Sleep architectureCPrognostic claimRead the review
Time-restricted eatingCIntervention claimRead the review
The reviews
  1. 01

    NAD precursors: nicotinamide mononucleotide and nicotinamide riboside

    Raising blood NAD metabolites is well demonstrated. Changing the trajectory of human ageing is not the same claim, and it is the one the supplement market makes.

    Grade D · Intervention claim
  2. 02

    Metformin for healthspan

    The best characterised drug in the field, and still without a trial that tests the claim being made for it. The observational signal is real and so are the reasons to distrust it.

    Grade C · Intervention claim
  3. 03

    Rapamycin and mTOR

    The most convincing animal lifespan data in the field, attached to an immunosuppressant with real risks and no long human ageing trial. Both halves of that sentence matter.

    Grade D · Intervention claim
  4. 04

    Senolytics: the current state

    Clearing senescent cells is one of the better ideas in ageing biology. Whether it can be done safely and usefully in a person is an open question with early answers only.

    Grade D · Intervention claim
  5. 05

    VO2 max as a longevity marker

    The single measurement most consistently associated with how long people live. That is a prognostic claim, and it should not be confused with proof that raising it causes the benefit.

    Grade A · Prognostic claim
  6. 06

    Resistance training and mortality

    Strong randomised evidence for function, strength and falls. Weaker observational evidence for mortality, resting on self-reported exposure and an odd shape at the top of the range.

    Grade B · Prognostic claim
  7. 07

    Sleep architecture and ageing

    Sleep changes measurably with age and poor sleep tracks poor outcomes. Which way the causal arrow points, and whether treating sleep changes anything downstream, is much less clear.

    Grade C · Prognostic claim
  8. 08

    Time-restricted eating

    One of the few interventions here with genuine randomised human evidence. The trials are short, and when calories are matched the additional effect of the window is small.

    Grade C · Intervention claim
The explainers

Method rather than substance. These apply to any health claim, in any field, from any source.

  1. 01

    How to read a clinical trial

    Six things to check before you believe a trial. Most of them are in the parts of the paper nobody reads.

    Method
  2. 02

    Surrogate endpoints, and why they mislead

    A marker moves. Nobody gets better. This is the most reliably repeated failure in preventative medicine, and the reasoning behind it is worth understanding once.

    Method
  3. 03

    Biological age tests: what they measure

    The output is a number of years. What produced it is a statistical model trained to predict something, and which something matters enormously.

    Method
  4. 04

    Supplement regulation in the UK

    A supplement on a British shelf has not been assessed for whether it works. Understanding what the system does check is the point of this explainer.

    Method
Analysis

How longevity and aesthetic medicine are delivered, chosen and paid for in the United Kingdom. Practice and market rather than graded claims.

  1. 01

    The aesthetic clinic evolution: why branding, design and digital experience now define clinical success

    Presentation is not the opposite of clinical quality. It is now the channel through which most patients try to judge it, which is a problem worth taking seriously.

    Analysis
  2. 02

    The complete guide to modern aesthetic medicine

    A structural guide to the field: the treatment families, the evidence behind each, the regulatory floor, and the questions that decide the outcome.

    Analysis
  3. 03

    Longevity and aesthetics: the future of ageing well in London

    The two fields are converging commercially faster than they are converging scientifically. A guide to telling the difference.

    Analysis
  4. 04

    The future of longevity: revolutionary anti-ageing innovations transforming healthcare

    Five fields described as revolutionary. Where each one genuinely stands, measured against the evidence rather than the announcement.

    Analysis
Regrade notices

Grades change when the evidence changes. Leave an address and we will tell you when one does, or when a new review is published.

Regrade notices and new reviews only. No promotions, no third parties, and you can stop at any time.